Risk factors for the development of atrial fibrillation on ibrutinib treatment.
Adenine
/ analogs & derivatives
Aged
Atrial Fibrillation
/ complications
Comorbidity
Electrocardiography
Female
Heart Failure
/ diagnosis
Humans
Incidence
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasms
/ complications
Patient Outcome Assessment
Piperidines
Protein Kinase Inhibitors
/ administration & dosage
Pyrazoles
/ administration & dosage
Pyrimidines
/ administration & dosage
Retrospective Studies
Risk Factors
Atrial fibrillation
Bruton’s tyrosine kinase inhibitor
cardio-oncology
heart failure
ibrutinib
left atrial abnormality
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
8
2
2019
medline:
21
7
2020
entrez:
8
2
2019
Statut:
ppublish
Résumé
Ibrutinib increases the risk of atrial fibrillation (AF), but the associated risk factors are not clearly defined. We performed retrospective review of ibrutinib-treated patients in a large academic practice to identify risk factors for new-onset AF. Variables with
Identifiants
pubmed: 30730240
doi: 10.1080/10428194.2018.1533129
doi:
Substances chimiques
Piperidines
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1447-1453Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States